Jin-Ping Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jin-Ping Li has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Israel Vlodavsky
2 shared publicationsAndreas Digre
Department of Medical Biochemistry and Microbiology, University of Uppsala, Uppsala, Sweden
1 shared publication- Baoxu Huang
China Animal Health and Epidemiology Centre, Ministry of Agriculture, People's Republic of China
1 shared publication - Benito Casu
G. Ronzoni Institute for Chemical and Biochemical Research, Milan, Italy
1 shared publication Bo Wang
Department of Medical Biochemistry and Microbiology, University of Uppsala, Uppsala, Sweden
1 shared publicationGuang-Yu Hou
China Animal Health & Epidemiology Center, Qingdao 266032, China
1 shared publication
Latest Publications
- 1 September 2015
- Published by Elsevier in Journal of Virological Methods
- Vol. 222, 202-205
Comparison of three media for transport and storage of the samples collected for detection of avian influenza virus
- 1 September 2015
- Published by Elsevier in Journal of Virological Methods
- Vol. 222, 202-205
Comparison of three media for transport and storage of the samples collected for detection of avian influenza virus
- 15 August 2012
- Published by Walter de Gruyter GmbH
- p. 824-854
8.8 Heparanase, a multifaceted protein involved in cancer, chronic inflammation, and kidney dysfunction
- 15 August 2012
- Published by Walter de Gruyter GmbH
- p. 824-854
8.8 Heparanase, a multifaceted protein involved in cancer, chronic inflammation, and kidney dysfunction
- Open Access
- 10 July 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (7) , e39899
Accelerated Resolution of AA Amyloid in Heparanase Knockout Mice Is Associated with Matrix Metalloproteases
AA-amyloidosis is a disease characterized by abnormal deposition of serum A amyloid (SAA) peptide along with other components in various organs. The disease is a complication of inflammatory conditions that cause persistent high levels of the acute phase reactant SAA in plasma. In experimental animal models, the deposited amyloid is resolved when the inflammation is stopped, suggesting that there is an efficient clearance mechanism for the amyloid. As heparan sulfate (HS) is one of the major components in the amyloid, its metabolism is expected to affect the pathology of AA amyloidosis. In this study, we investigated the effect of heparanase, a HS degradation enzyme, in resolution of the AA amyloid. The transgenic mice deficient in heparanase (Hpa-KO) produced a similar level of SAA in plasma as the wildtype control (Ctr) mice upon induction by injection of AEF (amyloid enhancing factor) and inflammatory stimuli. The induction resulted in formation of SAA amyloid 7-days post treatment in the spleen that displayed a comparable degree of amyloid load in both groups. The amyloid became significantly less in the Hpa-KO spleen than in the Ctr spleen 10-days post treatment, and was completely resolved in the Hpa-KO spleen on day 21 post induction, while a substantial amount was still detected in the Ctr spleen. The rapid clearance of the amyloid in the Hpa-KO mice can be ascribed to upregulated matrix metalloproteases (MMPs) that are believed to contribute to degradation of the protein components in the AA amyloid. The results indicate that both heparanase and MMPs play important parts in the pathological process of AA amyloidosis.
- 10 July 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (7) , e39899
Open AccessAccelerated Resolution of AA Amyloid in Heparanase Knockout Mice Is Associated with Matrix Metalloproteases
AA-amyloidosis is a disease characterized by abnormal deposition of serum A amyloid (SAA) peptide along with other components in various organs. The disease is a complication of inflammatory conditions that cause persistent high levels of the acute phase reactant SAA in plasma. In experimental animal models, the deposited amyloid is resolved when the inflammation is stopped, suggesting that there is an efficient clearance mechanism for the amyloid. As heparan sulfate (HS) is one of the major components in the amyloid, its metabolism is expected to affect the pathology of AA amyloidosis. In this study, we investigated the effect of heparanase, a HS degradation enzyme, in resolution of the AA amyloid. The transgenic mice deficient in heparanase (Hpa-KO) produced a similar level of SAA in plasma as the wildtype control (Ctr) mice upon induction by injection of AEF (amyloid enhancing factor) and inflammatory stimuli. The induction resulted in formation of SAA amyloid 7-days post treatment in the spleen that displayed a comparable degree of amyloid load in both groups. The amyloid became significantly less in the Hpa-KO spleen than in the Ctr spleen 10-days post treatment, and was completely resolved in the Hpa-KO spleen on day 21 post induction, while a substantial amount was still detected in the Ctr spleen. The rapid clearance of the amyloid in the Hpa-KO mice can be ascribed to upregulated matrix metalloproteases (MMPs) that are believed to contribute to degradation of the protein components in the AA amyloid. The results indicate that both heparanase and MMPs play important parts in the pathological process of AA amyloidosis.